Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Kiniksa Pharmaceuticals International (KNSA) EBITDA Margin (2021 - 2025)

Kiniksa Pharmaceuticals International (KNSA) has disclosed EBITDA Margin for 5 consecutive years, with 7.09% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBITDA Margin rose 1444.0% year-over-year to 7.09%, compared with a TTM value of 8.73% through Dec 2025, up 1897.0%, and an annual FY2025 reading of 8.73%, up 1897.0% over the prior year.
  • EBITDA Margin was 7.09% for Q4 2025 at Kiniksa Pharmaceuticals International, down from 10.14% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 226.07% in Q3 2022 and bottomed at 253.13% in Q3 2021.
  • Average EBITDA Margin over 5 years is 21.17%, with a median of 5.51% recorded in 2024.
  • The sharpest move saw EBITDA Margin soared 47920bps in 2022, then crashed -24675bps in 2023.
  • Year by year, EBITDA Margin stood at 193.94% in 2021, then soared by 98bps to 3.09% in 2022, then surged by 1081bps to 30.27% in 2023, then plummeted by -124bps to 7.35% in 2024, then skyrocketed by 196bps to 7.09% in 2025.
  • Business Quant data shows EBITDA Margin for KNSA at 7.09% in Q4 2025, 10.14% in Q3 2025, and 11.44% in Q2 2025.